{
    "id": "correct_subsidiary_00103_1",
    "rank": 50,
    "data": {
        "url": "https://en.wikipedia.org/wiki/Foundation_Medicine",
        "read_more_link": "",
        "language": "en",
        "title": "Foundation Medicine",
        "top_image": "https://en.wikipedia.org/static/favicon/wikipedia.ico",
        "meta_img": "https://en.wikipedia.org/static/favicon/wikipedia.ico",
        "images": [
            "https://en.wikipedia.org/static/images/icons/wikipedia.png",
            "https://en.wikipedia.org/static/images/mobile/copyright/wikipedia-wordmark-en.svg",
            "https://en.wikipedia.org/static/images/mobile/copyright/wikipedia-tagline-en.svg",
            "https://upload.wikimedia.org/wikipedia/commons/thumb/e/eb/FMI.png/220px-FMI.png",
            "https://upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png",
            "https://login.wikimedia.org/wiki/Special:CentralAutoLogin/start?type=1x1",
            "https://en.wikipedia.org/static/images/footer/wikimedia-button.svg",
            "https://en.wikipedia.org/static/images/footer/poweredby_mediawiki.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Contributors to Wikimedia projects"
        ],
        "publish_date": "2015-01-20T01:16:19+00:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "/static/apple-touch/wikipedia.png",
        "meta_site_name": "",
        "canonical_link": "https://en.wikipedia.org/wiki/Foundation_Medicine",
        "text": "American genomics company\n\nFoundation Medicine, Inc. is an American company based in Cambridge, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.[2]\n\nFoundation Medicine was founded in Cambridge, Massachusetts.[3] The company was conceived after Broad Institute researchers Levi Garraway and Matthew Meyerson published a 2007 paper detailing a method for large-panel testing of 238 DNA mutations.[4]\n\nFoundation Medicine launched in 2010 with a $25 million Series A financing led by Third Rock Ventures.[5] The company released its first commercial assay, or test, called FoundationOne in 2012.[6] The company also began partnering with pharmaceutical companies to analyze patient samples.[4] The first such program was piloted with Novartis in 2011,[5] and by 2018, the company had more than 30 partnerships.[7]\n\nFoundation Medicine launched its second test, a hematological biomarker assay called FoundationOneHeme, in 2013.[8] The company held its initial public offering in August 2013.[9] The following year, Priority Health in Michigan became the first healthcare plan in the United States to cover the company's tests.[10]\n\nIn 2016, using FoundationCore data, Foundation Medicine released anonymized records detailing genomic data on cancers from 18,000 adult patients to the National Cancer Institute's (NCI) Genomic Data Commons (GDC) portal.[11]\n\nIn 2018, Roche acquired Foundation Medicine, and currently operates it as a subsidiary.[12][13]\n\nGuardant Health sued Foundation Medicine over patents in 2019â€“2020.[14][15] In 2021, Guardant Health licensed intellectual property to Foundation Medicine for $25 million in a settlement.[16]\n\nFoundation Medicine's products include genomic tests for solid tumors and blood-based cancers and sarcomas,[17] as well as data services.\n\nFoundationOne CDx is a CGP test providing information for five tumor types: ovarian, lung, breast, colorectal, and melanoma.[18]\n\nFoundationOne Liquid\n\nFoundationOne Heme[8]\n\nThe company's FoundationCore database contains more than 300,000 genomic profiles sourced from the results of the company's assays as well as information on over 150 subtypes of cancer.[19]"
    }
}